PDS 0102
Alternative Names: PDS-0102; Versamune®-TARPLatest Information Update: 22 Nov 2021
At a glance
- Originator PDS Biotechnology Corporation
- Developer National Cancer Institute (USA); PDS Biotechnology Corporation
- Class Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Breast cancer; Prostate cancer
Most Recent Events
- 08 Nov 2021 T-cell receptor gamma alternate reading frame protein (TARP) licensed to PDS Biotechnology
- 17 Jun 2021 PDS Biotechnology plans clinical trials for Acute myeloid leukaemia, Breast cancer and Prostate cancer (SC, Injection) in 2022
- 01 Jun 2021 PDS 0102 is available for licensing as of 18 May 2021. https://pdsbiotech.com/versamune-platform/partnerships